Foroogh Alborzi Avanaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Foroogh Alborzi Avanaki has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Mohammad Taher
Department of Gastroenterology and Hepatology, Imam Khomeini Hospital Complex Tehran University of Medical Sciences Tehran Iran
2 shared publications- Abbas Yadegar
Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication Afsaneh Mirshahvelayati
Dr. Abidi Pharmaceuticals Company Tehran Iran
1 shared publication- Amir Sadeghi
Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases Shahid Beheshti University of Medical Sciences Tehran Iran
1 shared publication - Anahita Sadeghi
Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Aryan Salahi‐Niri
Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- 16 May 2026
- Published by Wiley in Helicobacter
- Vol. 31 (3) , e70137
First Report of National Consensus Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Iran
Background: Helicobacter pylori infection remains a major public health concern in Iran, where high prevalence, alarming antibiotic resistance, and significant gastric cancer burden necessitate a unified and evidence‐based national strategy. Despite the availability of international guidelines, gaps in clinical practice persist due to local epidemiology, resistance patterns, and diagnostic challenges. This study presents the first national Iranian consensus guideline for the diagnosis and management of H. pylori infection. Methods: A multidisciplinary panel of experts from leading Iranian gastroenterology centers convened between August 2023 and October 2025. Using the GRADE framework, the scientific committee conducted systematic literature reviews and formulated evidence‐based statements across diagnostic, therapeutic, and clinical management domains. Consensus was defined as ≥ 80% agreement. Twelve structured meetings, including a final hybrid national consensus conference, were held to refine recommendations. Results: The guideline delivers 35 evidence‐graded statements addressing indications for testing and treatment, optimal diagnostic modalities, and treatment pathways. Key recommendations include a strong preference for non‐invasive testing in patients under 45 without alarm features, endoscopic evaluation with targeted biopsies in high‐risk groups, and confirmation of eradication using urea breath test (UBT) or monoclonal stool antigen test (SAT) at ≥ 4 weeks post‐treatment. Given Iran's high clarithromycin resistance (> 20%), a course of 10–14 days bismuth quadruple therapy (BQT) is recommended as first‐line treatment, with non‐bismuth concomitant therapy as an alternative. Susceptibility‐guided therapy is encouraged when feasible, particularly after treatment failure. High‐dose proton pump inhibitor (PPI) or potassium competitive acid blocker (P‐CAB)‐based acid suppression is emphasized to enhance eradication efficacy. Special considerations are provided for renal/hepatic impairment and drug interactions. Conclusion: This national guideline provides a standardized, evidence‐based framework for improving H. pylori diagnosis and management. By integrating local antimicrobial resistance patterns and practical clinical considerations, the guideline helps optimize eradication rates, reinforce antibiotic stewardship, and contribute to gastric cancer prevention efforts across Iran.
- 16 May 2026
- Published by Wiley in Helicobacter
- Vol. 31 (3) , e70137
First Report of National Consensus Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Iran
Background: Helicobacter pylori infection remains a major public health concern in Iran, where high prevalence, alarming antibiotic resistance, and significant gastric cancer burden necessitate a unified and evidence‐based national strategy. Despite the availability of international guidelines, gaps in clinical practice persist due to local epidemiology, resistance patterns, and diagnostic challenges. This study presents the first national Iranian consensus guideline for the diagnosis and management of H. pylori infection. Methods: A multidisciplinary panel of experts from leading Iranian gastroenterology centers convened between August 2023 and October 2025. Using the GRADE framework, the scientific committee conducted systematic literature reviews and formulated evidence‐based statements across diagnostic, therapeutic, and clinical management domains. Consensus was defined as ≥ 80% agreement. Twelve structured meetings, including a final hybrid national consensus conference, were held to refine recommendations. Results: The guideline delivers 35 evidence‐graded statements addressing indications for testing and treatment, optimal diagnostic modalities, and treatment pathways. Key recommendations include a strong preference for non‐invasive testing in patients under 45 without alarm features, endoscopic evaluation with targeted biopsies in high‐risk groups, and confirmation of eradication using urea breath test (UBT) or monoclonal stool antigen test (SAT) at ≥ 4 weeks post‐treatment. Given Iran's high clarithromycin resistance (> 20%), a course of 10–14 days bismuth quadruple therapy (BQT) is recommended as first‐line treatment, with non‐bismuth concomitant therapy as an alternative. Susceptibility‐guided therapy is encouraged when feasible, particularly after treatment failure. High‐dose proton pump inhibitor (PPI) or potassium competitive acid blocker (P‐CAB)‐based acid suppression is emphasized to enhance eradication efficacy. Special considerations are provided for renal/hepatic impairment and drug interactions. Conclusion: This national guideline provides a standardized, evidence‐based framework for improving H. pylori diagnosis and management. By integrating local antimicrobial resistance patterns and practical clinical considerations, the guideline helps optimize eradication rates, reinforce antibiotic stewardship, and contribute to gastric cancer prevention efforts across Iran.
- Open Access
- 30 January 2023
- Published by Maad Rayan Publishing Company in Middle East Journal of Digestive Diseases
- Vol. 15 (1) , 45-52
Biofeedback Treatment Can Improve Clinical Condition and Quality of Life in Patients with Pelvic Floor Dyssynergy with Irritable Bowel Syndrome: A Prospective Cohort Study
Background: Chronic constipation is a common health concern. Defecatory disorders are considered one of the mechanisms of chronic idiopathic constipation. This study aimed to evaluate the effect of concurrent irritable bowel syndrome (IBS) on the success rate and response to biofeedback therapy in patients with chronic constipation and pelvic floor dyssynergia (PFD). Methods: This prospective cohort study was performed at the Imam Khomeini Hospital Complex in Tehran from October 2020 to July 2021. Patients aged 18–70 years with chronic constipation and PFD confirmed by clinical examination, anorectal manometry, balloon expulsion test, and/or defecography were included. All patients failed to respond to treatment with lifestyle modifications and laxative use. The diagnosis of IBS was based on the ROME IV criteria. Biofeedback was educated and recommended to all patients. We used three different metrics to assess the patient’s response to biofeedback: 1) constipation score (questionnaire), 2) lifestyle score (questionnaire), and 3) manometry findings (gastroenterologist report).Results: Forty patients were included in the final analysis, of which 7 men (17.5%) and 21 (52.2%) had IBS. The mean age of the study population was 37.7 ± 11.4. The average resting pressure decreased in response to treatment; however, this decrease was statistically significant only in non-IBS patients (P = 0.007). Patients with and without IBS showed an increase in the percentage of anal sphincter relaxation in response to treatment, but this difference was not statistically significant. Although the first sensation decreased in both groups, this decrease was not statistically significant. Overall, the clinical response was the same across IBS and non-IBS patients, but constipation and lifestyle scores decreased significantly in both groups of patients with and without IBS (P < 0.001).Conclusion: Biofeedback treatment appears to improve the clinical condition and quality of life of patients with PFD. Considering that a better effect of biofeedback in correcting some manometric parameters has been seen in patients with IBS, it seems that paying attention to the association between these two diseases can be helpful in deciding on treatment.
- 30 January 2023
- Published by Maad Rayan Publishing Company in Middle East Journal of Digestive Diseases
- Vol. 15 (1) , 45-52
Open AccessBiofeedback Treatment Can Improve Clinical Condition and Quality of Life in Patients with Pelvic Floor Dyssynergy with Irritable Bowel Syndrome: A Prospective Cohort Study
Background: Chronic constipation is a common health concern. Defecatory disorders are considered one of the mechanisms of chronic idiopathic constipation. This study aimed to evaluate the effect of concurrent irritable bowel syndrome (IBS) on the success rate and response to biofeedback therapy in patients with chronic constipation and pelvic floor dyssynergia (PFD). Methods: This prospective cohort study was performed at the Imam Khomeini Hospital Complex in Tehran from October 2020 to July 2021. Patients aged 18–70 years with chronic constipation and PFD confirmed by clinical examination, anorectal manometry, balloon expulsion test, and/or defecography were included. All patients failed to respond to treatment with lifestyle modifications and laxative use. The diagnosis of IBS was based on the ROME IV criteria. Biofeedback was educated and recommended to all patients. We used three different metrics to assess the patient’s response to biofeedback: 1) constipation score (questionnaire), 2) lifestyle score (questionnaire), and 3) manometry findings (gastroenterologist report).Results: Forty patients were included in the final analysis, of which 7 men (17.5%) and 21 (52.2%) had IBS. The mean age of the study population was 37.7 ± 11.4. The average resting pressure decreased in response to treatment; however, this decrease was statistically significant only in non-IBS patients (P = 0.007). Patients with and without IBS showed an increase in the percentage of anal sphincter relaxation in response to treatment, but this difference was not statistically significant. Although the first sensation decreased in both groups, this decrease was not statistically significant. Overall, the clinical response was the same across IBS and non-IBS patients, but constipation and lifestyle scores decreased significantly in both groups of patients with and without IBS (P < 0.001).Conclusion: Biofeedback treatment appears to improve the clinical condition and quality of life of patients with PFD. Considering that a better effect of biofeedback in correcting some manometric parameters has been seen in patients with IBS, it seems that paying attention to the association between these two diseases can be helpful in deciding on treatment.
- Open Access
- 1 January 2020
- Published by Korean Society of Clinical Nutrition in Clinical Nutrition Research
- Vol. 9 (4) , 284-295
Effect of Selenium Supplementation on Expression of SIRT1 and PGC-1α Genes in Ulcerative Colitis Patients: a Double Blind Randomized Clinical Trial
Khazdouz M, et al. Clin Nutr Res. 2020 Oct;9(4):284-295. https://doi.org/10.7762/cnr.2020.9.4.284
- 1 January 2020
- Published by Korean Society of Clinical Nutrition in Clinical Nutrition Research
- Vol. 9 (4) , 284-295
Open AccessEffect of Selenium Supplementation on Expression of SIRT1 and PGC-1α Genes in Ulcerative Colitis Patients: a Double Blind Randomized Clinical Trial
Khazdouz M, et al. Clin Nutr Res. 2020 Oct;9(4):284-295. https://doi.org/10.7762/cnr.2020.9.4.284